China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China flag China · Delayed Price · Currency is CNY
17.47
-0.38 (-2.13%)
May 12, 2026, 3:04 PM CST

SHE:300294 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,8432,0581,7342,6512,7612,645
Other Revenue
0.990.990.790.85-2.225.21
1,8442,0591,7352,6522,7592,651
Revenue Growth (YoY)
1.21%18.69%-34.58%-3.87%4.08%5.47%
Cost of Revenue
968.481,043615.971,2591,2551,187
Gross Profit
875.861,0161,1191,3931,5041,463
Selling, General & Admin
622.92648.36603.65774.85923.64969.52
Research & Development
48.2254.5566.8967.749.5859.29
Other Operating Expenses
35.2718.2317.4718.9820.8319.99
Operating Expenses
721.87742.66696.81863.9996.861,049
Operating Income
153.99272.95422.12529.38507.16414.49
Interest Expense
-1.7-1.16-0.66-0.46-0.62-10.53
Interest & Investment Income
39.5737.4242.4945.3164.9363.9
Currency Exchange Gain (Loss)
6.616.61-2.77---
Other Non Operating Income (Expenses)
3.61-2.540.87-0.434.02-8.3
EBT Excluding Unusual Items
202.09313.28462.05573.81575.49459.57
Impairment of Goodwill
-110.47-110.47-72.61-298.41--
Gain (Loss) on Sale of Investments
41.9759.9865.5885.74-10.71
Gain (Loss) on Sale of Assets
4.735.1-0.611.30.07-0.87
Asset Writedown
-199.04-199.11-11.18-28.31-51.03-36.37
Other Unusual Items
37.2535.134.4919.597.4710.08
Pretax Income
-23.47103.88477.71353.71532443.12
Income Tax Expense
-26.85-8.7681.19105.5686.5184.84
Earnings From Continuing Operations
3.38112.64396.53248.15445.49358.28
Minority Interest in Earnings
0.050.060.46-10.68-13.29-13.75
Net Income
3.44112.7396.99237.47432.2344.53
Net Income to Common
3.44112.7396.99237.47432.2344.53
Net Income Growth
-99.11%-71.61%67.18%-45.06%25.45%32.48%
Shares Outstanding (Basic)
514512503505503436
Shares Outstanding (Diluted)
514512503505503436
Shares Change (YoY)
2.65%1.94%-0.54%0.53%15.24%2.30%
EPS (Basic)
0.010.220.790.470.860.79
EPS (Diluted)
0.010.220.790.470.860.79
EPS Growth
-99.13%-72.15%68.08%-45.35%8.86%29.51%
Free Cash Flow
-627.32-474.15101.99554.23458.031,277
Free Cash Flow Per Share
-1.22-0.930.201.100.912.93
Dividend Per Share
0.2230.2230.3200.3000.2000.150
Dividend Growth
-30.31%-30.31%6.67%50.00%33.33%130.77%
Gross Margin
47.49%49.32%64.50%52.54%54.52%55.21%
Operating Margin
8.35%13.26%24.33%19.96%18.38%15.64%
Profit Margin
0.19%5.47%22.88%8.95%15.67%13.00%
Free Cash Flow Margin
-34.01%-23.03%5.88%20.90%16.60%48.19%
EBITDA
307.62415.82521.95624.38600.38510.65
EBITDA Margin
16.68%20.19%30.09%23.54%21.76%19.27%
D&A For EBITDA
153.63142.8799.8294.9993.2296.16
EBIT
153.99272.95422.12529.38507.16414.49
EBIT Margin
8.35%13.26%24.33%19.96%18.38%15.64%
Effective Tax Rate
--16.99%29.84%16.26%19.15%
Revenue as Reported
1,8442,0591,7352,6522,7592,651
Advertising Expenses
-4.553.262.731.822.5
Source: S&P Global Market Intelligence. Standard template. Financial Sources.